Spots Global Cancer Trial Database for Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer

Official Title: Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)

Study ID: NCT00022620

Conditions

Endometrial Cancer

Interventions

paclitaxel

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer.

Detailed Description: OBJECTIVES: * Determine the therapeutic activity of paclitaxel in patients with refractory or recurrent endometrial papillary carcinoma. * Determine the objective response and duration of response in patients treated with this regimen. * Determine the acute side effects of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 12 weeks. PROJECTED ACCRUAL: Approximately 16-29 patients will be accrued for this study.